Cell line · CVCL_1304
Papers76
1 to 20 of 76
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Nuclear localization of the glutaminyl-tRNA synthetase QARS reveals its role in DNA damage response in ovarian cancer. | Nat Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| High-throughput combination screening of Pidnarulex and other G-quadruplex ligands in multi-cell type tumor spheroids. | SLAS Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile. | Mol Cancer Ther | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The anticancer effect of the HDAC inhibitor belinostat is enhanced by inhibitors of Bcl-xL or Mcl-1 in ovarian cancer. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| IMGN853 Induces Autophagic Cell Death in Combination Therapy for Ovarian Cancer. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Physiochemical and functional evaluation of the first-in-class anti-cancer IgE antibody drug, MOv18, through process development and good manufacturing practice production. | MAbs | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Eradication of Therapy-Resistant Cancer Stem Cells by Novel Telmisartan Derivatives. | J Med Chem | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Inhibiting ADAM17 enhances the efficacy of olaparib in ovarian cancer spheroids. | Sci Rep | 2024 | Its Methods give the RRID and name the line | PubMed | |
| HTS384 NCI60: The Next Phase of the NCI60 Screen. | Cancer Res | 2024 | Cellosaurus cites it, and its Methods give the RRID and name the line | PubMed | |
| Association of changes in expression of HDAC and SIRT genes after drug treatment with cancer cell line sensitivity to kinase inhibitors. | Epigenetics | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation. | Nat Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| A NOTCH1 Mutation Found in a Newly Established Ovarian Cancer Cell Line (FDOVL) Promotes Lymph Node Metastasis in Ovarian Cancer. | Int J Mol Sci | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes. | Br J Cancer | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| G6PD inhibition sensitizes ovarian cancer cells to oxidative stress in the metastatic omental microenvironment. | Cell Rep | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Loss of Claudin-4 Reduces DNA Damage Repair and Increases Sensitivity to PARP Inhibitors. | Mol Cancer Ther | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Ants detect cancer cells through volatile organic compounds. | iScience | 2022 | Its Methods give the RRID and name the line | PubMed | |
| PGC1α/β Expression Predicts Therapeutic Response to Oxidative Phosphorylation Inhibition in Ovarian Cancer. | Cancer Res | 2022 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1304/papers